Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

This investigator-initiated, double-blind, placebo-controlled study evaluates the safety and tolerability, biological activity, and preliminary efficacy of LD IL-2 in 38 patients with...

Related Keywords

United States ,Houston ,Texas ,Americans ,Fred Grossman ,Jason Thonhoff ,Stanley Appel ,David Beers ,Nasdaq ,Centers For Disease ,Alzheimer Association ,Gates Foundation ,Houston Methodist Research Institute ,Coya Therapeutics Inc ,Coya Therapeutics ,Alireza Faridar ,Houston Methodist Hospital ,Mini Mental State Examination ,Disease Control ,About Coya Therapeutics ,Amyotrophic Lateral Sclerosis ,Frontotemporal Dementia ,